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Abstract 
 
 gC1qR is an ubiquitously expressed cell protein that interacts with the globular heads of 
C1q (gC1q) and many other ligands. In this study, the 7.8 kb human gC1q-R/p32 (C1qBP) 
gene was cloned and found to consist of 6 exons and 5 introns. Analysis of a 1.3 kb DNA 
fragment at the 5’ flanking region of this gene revealed the presence of multiple TATA, 
CCAAT and Sp1 binding sites. Luciferase reporter assays performed in different human cell 
lines demonstrated that the reporter gene was ubiquitously driven by this 1.3 kb fragment. 
Subsequent 5' and 3' deletion of this fragment confined promoter elements to within 400 bp 
upstream of the translational start site. Since the removal of the 8-bp consensus TATATATA 
at -399/-406 and CCAAT at -410/414 did not significantly affect the transcription efficiency 
of the promoter, GC rich sequences between this TATA box and the translation start site may 
be very important for the promoter activity of the C1qBP gene. One out of seven GC rich 
sequences in this region bind specifically to PANC-1 nuclear extracts, and the transcription 
factor Sp1 was shown to bind to this GC rich sequence by the supershift assay. Primer 
extension analysis mapped three major transcription start regions. The farthest transcription 
start site is 49bp upstream of the ATG translation initiation codon and is in close proximity of 
the specific SP1 binding site.   
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1. Introduction 
 
 gC1q-R is a biologically important, widely distributed, multiligand binding and 
multifunctional protein [1]. Numerous reports have claimed that gC1qR and its homologue 
could be isolated or identified in various cellular compartments, including plasma membrane, 
cytoplasm, mitochondria and nucleus. gC1qR isolated from the plasma membrane was 
originally characterized as a high affinity C1q-binding protein [2], and later many reports 
showed that gC1q-R could interact with several proteins of the intrinsic 
coagulation/bradykinin forming cascade, including high molecular weight kininogen[3], 
Factor XII [4], fibrinogen [5] and multimeric vitronectin [6]. Conversely, intracellular gC1qR 
was shown to interact and subsequently down-regulate the surface expression of the 
a1b-adrenergic receptor [7] as well as bind to the kinase domain of protein kinase Cm and 
thus prevent its substrate-phosphorylation activity [8]. In addition, gC1qR was also reported 
to bind to a nuclear splicing factor SF2 and to many viral proteins, including HIV-1 Tat[9] 
and Rev[10], core protein V of adenovirus[11], EBNA-1 of Epstein-Barr virus[12] and open 
reading frame P of herpes simplex virus[13], implying that gC1qR may play a role in 
virus-host interaction.  
The full length cDNA of gC1qR encodes a pre-pro-protein of 282 residues from which a 
73-residue-long N-terminal segment is removed by site-specific cleavage to generate the 
mature gC1q-R [2]. It was shown that the fusion of the residues 1-81 or 1-33 of the 
pre-pro-protein to the N-terminus of the green fluorescent protein directed the fusion protein 
to mitochondria [14]. However, the findings of Dedia et al [14] do not exclude the possibility 
that gC1qR, like many other proteins, could be exported from the mitochrondria by an 
unknown mechanism [15]. This is supported by a recent report showing that anti-gC1qR 
monoclonal antibody can reverse the anti- proliferation effects of Hepatitis virus C core 
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antigen on activated T cells[16].  
 The human C1qBP gene was assigned to human chromosome 17q13.3 [17]. High degree 
of amino acid identity exists between the human, rat and mouse gC1qR cDNA sequences [18]. 
In this study, the full length gene of human gC1qR was cloned and its exon-intron boundries 
were revealed. Furthermore, the transcription start site and its promoter elements were also 
mapped and characterized. 
 
2. Materials and Methods 
 
2.1. Screening of human genomic library 
 A human genomic library in bacteriophage EMBL3 was purchased from Clontech, 
California, USA (Cat. No. HL1067J). The human cDNA of the C1qBP gene was used as the 
probe for library screening [2]. The cDNA insert was released from its vector and gel-purified 
before radiolabeling with 32P-dATP by the random priming method. Positive plaques were 
picked, replated and rescreened until single positive plaques were picked. The insert in a 
positive plaque was digested with various restriction enzymes and the positive fragments were 
mapped by southern blot analysis. Six overlapping subclones (Figure 1) were obtained by 
inserting the positive fragments into the plasmid pBluescript. Each subclone was sequenced 
by primer walking method using the ABI Prism 310 Genetic Analyzer (Applied Biosystems 
Hong Kong Limited, Hong Kong). 
 
2.2.  Sequence assembly and analysis 
 Sequence data were assembled and analyzed by DNA processing softwares including 
MAC DNASIS (Hitachi, Japan) and DNA Strider (Christian Marck, Service de Biochimie, 
Department de Biologie, Institut de Recherche Fondamentale, CEA, France).  Promoter 
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analysis was performed by the MatInspector Software (V 2.2) [19] on the world wide web 
(http://bioinformatics.weizmann. ac.il/transfac/). A transcription factor database (TRANSFAC 
V 4.0) was employed for the search of promoter elements [20]. 
 
2.3. Construction of expression plasmids for promoter assay 
 Various DNA fragments of the 5' upstream region of the human gC1qR gene (C1qBP) 
were obtained by PCR using subclone gI as the template. Restriction sites BglII or SacI were 
added to the 5' end of the primers (Table 1A) so that the PCR products can be easily 
subcloned into the corresponding restriction sites in the Dual-Luciferase reporter vector 
pGL3-Basic (Promega, Hong Kong). A nested family of 5' and 3' deletion clones (Table 2) 
were generated in this manner (Figure 4). 
 
2.4.  Cell culture, transient transfection and promoter assays 
 The human cell lines PANC-1 (ATCC no. CRL-1469), MDA-MB-231 (ATCC no. 
HTB-26), SVG P12 (ATCC no. CRL-8621), HuTu80 (ATCC no. HTB-40) and 293-EBNA 
(Invitrogen, no. R620-07) were selected for transient transfection studies.  SVG P12 and 
HuTu80 cells were cultured in MEM, (Life Technologies, Hong Kong); PANC-1, 
MDA-MB-231 and 293-EBNA cells were cultured in DMEM, high glucose (Life 
Technologies, Hong Kong).  All culture mediums were supplemented with 10%(v/v) fetal 
bovine serum (50 ml FBS in 500 ml medium) and 1X antibiotic-antimycotic mixture (Life 
Technologies, Hong Kong) at 37oC with 5% CO2. Plasmid DNA used for transfection was 
prepared using the Quantum prep Kit (BIORAD, Hong Kong), and treated with phenol 
chloroform before transfection. For transient transfection, cells were seeded onto 12-well 
plates (Costar, Corning Inc., USA) at a density of 1.0 X 105 cells /well. Co-transfection was 
performed 19 hours later using the LipofectAMINE PLUS ® Reagent (Life Technologies, 
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Hong Kong), with procedures performed according to the manufacturer's protocol. The molar 
ratio of the recombinant plasmid to be assayed and the internal control pRL-SV40 plasmid 
(Promega, Hong Kong) was kept at 1:1 in all transfection. Immediately after transfection, the 
cells were incubated in the medium without serum and antibiotics at 37oC with 5% CO2 for 
3.5 hr before changing into the complete medium. The cells were lysed at 39 hr 
post-transfection by washing the cells twice with 1X Phosphate Buffer Saline (PBS), followed 
by the addition of reporter Passive Lysis Buffer (Promega, Hong Kong). Dual-Luciferase 
reporter assay was performed according to the manufacturer's protocol (Dual-Luciferase 
Reported Assay kit, Promega, Hong Kong) using a luminometer (Lumat LB 9507, EG & G, 
Berthold) as the measuring apparatus. 
 
2.5.  RNA isolation and primer extension analysis 
Total cellular RNA was isolated from human cell line MDA-MB-231 by TRIzol reagent 
(Life Technologies, Hong Kong). Poly(A)+ RNA was extracted from 2 mg of total RNA using 
the PolyATract mRNA isolation kit (Promega, USA). Labeling of primer and primer 
extension reaction was performed using 1mg Poly(A)+ RNA with 10pmole antisense primer 
G1A2Bgl following the instruction of the Primer Extension System (Promega, USA). 4 ml of 
the primer extension reaction product was analyzed on 6%(w/v) acrylamide/7M urea 
sequencing gel. The size of the primer extension product was determined by comparison with 
a DNA sequence ladder generated with the same oligonucleotide primer using ERES3 
plasmid as a template. 
 
2.6.  Gel mobility shift assays 
The human cell line PANC-1 was selected for gel shift assays.  Cells were cultured as 
mentioned in section 2.4 to exponential phase and harvested.  End-labeling of 
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double-stranded oligos (Table 1B) was done by the Ready-To-Go T4 polynucleotide kinase 
labeling kit (Pharmacia) and [g-32P]ATP (5000 Ci/nmol) (Amersham, Arlington Heights, IL). 
Nuclear extracts preparation and gel shift assays were performed as earlier described [21], 
[22]. 
 
3. Results  
3.1. Genomic organization of the human C1qBP gene 
 Figure 1 is a schematic representation of the genomic organization of the gene, which, 
including its 5' and 3' flanking regions, spans about 7.8 kb. From the first codon of the 
initiation methionine till the stop codon of the gene, the gene spans 6055 bp (Figure 2). By 
alignment of the cDNA and the genomic sequences, intron-exon boundaries were defined. 
There are 6 exons and 5 introns in the C1qBP gene. The sizes of exons range from 94 bp 
(exon 3) to 232 bp (exon 1), and that of the introns range from 128 bp (intron 5) to 3156 bp 
(intron 2). Amino acid codons are split by introns 1 and 2 at the junctions of their adjacent 
exons. (Table 3)  A poly A signal is located at 369 bp from the stop codon. The entire 
genomic sequence has been deposited in the Genbank under Accession No: AF338439. 
 
3.2. Characterization of the 5'-flanking region of the human C1qBP gene  
 A 1.3 kb nucleotide sequence located upstream of the ATG initiation codon of the gene 
was analyzed (Figure 3) using the TRANSFAC transcription factor database. Putative 
promoter and enhancer elements including TATA boxes, CCAAT boxes, Octamers, Sp1 
binding sites, GATA sequences, E boxes and AP elements were identified by the software 
MatInspector. There are four putative TATA boxes (-806/-811, -614/-617, -446/-449 and 
-399/-406) and three putative CCAAT boxes (-1033/-1037, -460/-463 and -410/-414). The 
8-bp consensus TATA box with sequence TATATATA located at -399/-406 is the longest 
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TATA element found in the region, and it is in close proximity to a CCAAT box located at 
-410/414. Sp1 binding GC-rich motifs are also found throughout the 5'-flanking region of the 
gene, at positions -1309/-1314, -959/-965, -535/-540, -519/-524, -337/-342, -177/-182, 
-148/-154, -139/-144, -111/-118, -83/-90 and -51/-61.   
 A variety of consensus elements for transcription factors are also present, including an 
octamer site for the homeobox domain factor Oct-1 (-28/-34), several recognition sites for the 
putative zinc transcription factor GATA, which is expressed in high levels in the pancreas and 
gut-derived cells [23]. Other putative sites for enhancer elements, AP1, AP2, AP3 and AP4, 
heat-shock factor (HSF) [24], nuclear factor of activated T cells (NFAT) [25], AML 
transcription factor [26] and c-Ets-1 transcription factor [27] are also identified in the 5' 
flanking region.  
 
3.2 Determination of the transcription start sites  
A primer extension analysis was performed to determine the transcription start site of the 
gene.  As shown in figure 4, there are three regions detected with stronger intensities, each 
region was found with a number of individual start sites. These regions are the major 
transcription start sites.  The farthest extension band was observed at 49bp upstream of the 
ATG translation initiation codon and is an adenine residue. This nucleotide is positioned just 
downstream to an SP1-binding site found in the promoter region. All these regions lie within 
50bp upstream to the translation initiation codon. 
 
3.3. Mapping of the human gC1qR gene (C1qBP) promoter element in PANC-1 cells 
 To localize the essential promoter region for human gC1q-R gene expression, several 5' 
and 3' deletion clones were constructed by cloning various restriction fragments produced by 
PCR into a reporter vector pGL3-Basic. Since these fragments were cloned upstream to a 
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luciferase reporter gene, transcriptional activities of the promoter-luciferase cartridge could be 
studied by transfecting various clones to the human cell line PANC-1 (Figure 5). It was found 
that the essential region for promoting transcription is very close to the start site of translation. 
By comparing luciferase activities between constructs ERES 2 to ERES 7 and that of 
constructs ERES 7 with ERES 2H and 2P, the essential promoter region could be mapped to a 
region spanning from the translation start site to -364 bp. This observation is supported by the 
fact that no significant difference in the luciferase activities was observed upon deletion of the 
5' sequence from -364 to -1319 (ERES 7).  However, in the two constructs in which the 3' 
region was deleted, the luciferase activities were completely abolished. Since no 5' deletion 
studies were carried out beyond -364, we cannot conclude and finely map the essential 
promoter elements in the -1 to -365 region upstream of the translation start site. Experimental 
data also showed that inverting the 1.3 kb 5'flanking region (ERES 1) greatly decreased the 
transcription activities. 
 
3.4  Deletion analysis on the other human cell lines 
Three constructs, ERES 2, ERES 7 and ERES 2P were transfected to the other human 
cell lines to test the cell specificity of the promoter element as well as to map the element.  
All the four cell lines MDA-MB-231, SVG P12, 293-EBNA and HuTu80 showed enhanced 
level of luciferase activities for constructs ERES 2 and ERES 7, ranging from tens to 
hundreds folds depending on cell lines (Figure 6).  However, similar to the results obtained 
in PANC-1, deletion of the 3’ region of the promoter (ERES 2P) completely abolished the 
promoter-reporter luciferase activities in all of these four cell lines. It was surprising that the 
removal of the TATA box at -399/-406 and the CCAAT box at -410/414 in ERES 7 did not 
significantly affect the transcription efficiency of the promoter. This implied that there are 
strong promoter elements in the –1 to –364 region of the 5’ flanking region. 
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3.5  Interaction between DNA-specific nuclear protein factors and promoter elements 
In this –1 to –364 regions, seven GC rich sequences with high homology to the 
consensus SP1 binding site were identified (Figure 3).  In order to test if there is any nuclear 
factor interacting with these GC rich sequences, gel shift assays (Figure 7A) were performed 
with nuclear extracts of PANC-1 cells.  Seven pairs of synthetic oligonucleotides in both 
sense and antisense orientations (Table 1B) were designed based on these GC-rich motifs.  
Out of the eight oligo pairs (including a negative control that is not GC-rich), only the L6 
probe formed DNA-protein complexes with the nuclear extract.  In the competitive assay, 
decreased intensity of the hybridization bands was observed (Figure 7B) when the 
concentrations of the unlabeled L6 probe were 10 to 100 folds to the labeled L6 probe.  
When an unrelated DNA probe were used for the competition assay (Figure 7B), one 
(complex 1) out of the four bands also showed a reduced signal, indicating that complex 1 is a 
non-specific signal. To reveal the identity of the complexes, monoclonal anti-Sp1 antibodies 
(Research Diagnostics Inc., New Jersey) and BSA were mixed with the complexes in a super 
shift assay. It was observed that the DNA-protein complex 4 was only shifted by anti-Sp1 
antibodies but not by BSA, indicating that complex 4 is a complexes between oligonucleotide 
L6 and Sp1 (Figure 8). 
 
4. Discussion 
 Like the mouse gene, the human gC1qBP gene contains six exons and five introns and 
the sizes of each exon do not differ much except the exon 6 [28]. The exon 6 in human 
C1qBP gene is about 100 bp larger than the mouse gene, due to a longer 3' untranslated region 
defined by the polyadentylation sites. Even though the sizes of exons between the human and 
mouse genes are almost the same, three of the introns of the human C1qBP gene have 
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expanded sizes when compared to their mouse counterparts. The sizes of intron 2 in human 
and mouse genes are 3156 bp and 2071 bp, respectively, which makes the human gene 
approximately one kb larger than the mouse gene. 
 Promoter elements of the human gene were identified by computer analysis and 
transfection studies. Several TATA boxes and CCAAT boxes were found on the 1.3 kb 5' 
flanking region. TATA box is a crucial positioning component of the core promoter, and is 
usually located about 25 bp upstream of the transcription start site and it constitutes the only 
upstream promoter element that has a relatively fixed location with respect to the transcription 
start site. CCAAT boxes are often located close to the TATA boxes, but it can function at 
distances that vary considerably from the transcription start site in either orientation. Mutation 
studies have suggested that the CCAAT box play a strong role in determining the efficiency 
of the promoter; while its inclusion increases promoter strength. 
 Transcription start sites are usually located downstream in close proximity to TATA 
elements in the majority of promoters. However, the transcription start sites (-49 to -29) of the 
human C1qBP gene are around 350 bp from the closest TATA element (-399) found in the 5’ 
flanking region of the gene. The 5' flanking region of the human gene contains an 8-bp 
consensus TATA box with sequence TATATATA at -399/-406 and a CCAAT box at 
-410/414, whereas in mouse gene, the TATA box closest to the ATG start codon is located 
approximately at -306/-309 [29]. However, in the promoter studies, the construct ERES7 
which didn't carry any TATA nor CCAAT boxes still gave more than 90% transcription 
efficiency, indicating that none of the TATA boxes or CAAT boxes was essential for the 
transcription of Luciferase mRNA in the cell lines under test.  Instead, deletion studies 
carried out in all cell lines showed complete abolishment in promoter-reporter activity when 
the 364 bp adjacent to the initiation methionine was deleted (ERES 2P). This 364 bp promoter 
sequence, similar to the large stretch of GC-rich sequence in the mouse gene, especially from 
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nucleotides -1 to -200 (75% G+C content) [28], contains seven GC-rich Sp1 sites, which are 
frequently linked to the transcriptional control of genes lacking a functional TATA box.  As 
no TATA element was found to be essential for the activity of gC1qBP promoter, Sp1 sites in 
the upstream region close to the transcription start site are suggested to be very important for 
the promoter activity of the gene.  In fact, one out of these seven GC-rich Sp1 sites (-96 
to –76) was found to bind specifically to PANC-1 nuclear proteins in gel mobility shift assays, 
and one of these nuclear factors was further proved to be Sp1 binding factor in supershift 
assays employing anti-Sp1 antibodies.  These results show that binding of Sp1 to the SP1 
binding site located at around 80 bp upstream to the translation initiation codon may play an 
important role in transcription control in human gC1qBP gene. 
 With regards to the number of various transcription control elements in the 5'-flanking 
region, it may be possible that different transcription control elements are essential for the 
gene expression in different human cells. 
The three dimensional structure of gC1qR was revealed by X-ray crystallography. The 
mature protein molecule has one N-terminal a-helix followed by seven consecutive 
antiparallel b-strands and two C-terminal a-helices [29]. Three molecules form a dough-nut 
shape quaternary structure with an internal channel of 10 A diameter. By aligning the exon 
boundaries and the three dimensional structure, it is observed that: exon 1 encodes the first 77 
amino acid residues containing the mitochondria-targeting sequence[14]; exon 2 encodes the 
N-terminal a-helix and the first two b-strands; exon 3 encodes b-strand 3; exon 4 encodes 
b-strands 4 and 5; exon 5 encodes b-strands 6 and 7 and the last exon encodes for the 
C-terminal a-helices. As gC1qR was shown to be a multi-ligand binding protein, it would be 
interesting to map the binding sites on gC1qR to various ligands. 
More recently, gC1q-R was found to function as a receptor for the internalin B (InlB) 
invasion protein of Listeria monocytogenes [30], and to bind to protein A of Staphylococcus 
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aureus [31].  Another report showed that the hepatitis virus C core antigen can interact with 
gC1qR and the anti- proliferation effects of Hepatitis virus C core antigen on activated T cells 
can be reversed by anti-gC1qR monoclonal antibodies[16]. All these reports further suggest 
that gC1qR is a biologically important, widely distributed, multiligand binding and 
multifunctional protein [1]. 
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Figure Legends 
 
Figure 1.  The genomic organization of the human C1qBP gene. Exons are highlighted as 
dark boxes.  Dark, bold lines below the gene indicate the overlapping subclones.  Arrows 
indicate the position of sequencing primers and the approximate length sequenced by each 
primer.  Restriction enzyme sites are shown at locations above the gene. 
 
Figure 2.  DNA sequences of the human C1qBP gene.  The first nucleotide of the 
translation start codon ‘ATG’ is assigned as 1.  Exon-intron boundaries are shown.  All 
intronic sequences, the 5’flanking region of the gene and the 3’ flanking region as defined by 
the cDNA amino acid coding sequences, are shown as small letters.  A poly A signal located 
369bp from the stop codon was underlined. 
 
Figure 3.  Analysis of the 5’ flanking region of the human C1qBp gene.  The first 
nucleotide of the translation start codon ‘ATG’ (bolded) is assigned 1, and the preceding 
nucleotide is assigned –1.  All potential transcription factor binding sites, promoters and 
elements that may be responsible in transcription control are underlined and labeled below the 
line. 
 
Figure 4.  Primer extension analysis of the human C1qBP gene promoter.  Lanes 1 to 4 
are sequencing ladders generated by the same primer (G1A2).  Lane 5 is the primer 
extension reaction product. The position of the nucleotides marked on the left side of the gel 
was designated according to the translation initiation codon ATG, which was assigned as +1. 
Three regions of strong signal were identified. The farthest extension product was mapped at 
49 bp upstream to the ATG codon. 
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Figure 5.  Promoter deletion assay in PANC-1 cell. Schematic diagrams of various 
promoter-luciferase constructs were shown on the left.  Arrows indicate the orientation of 
the sequence.  Values indicated on top of arrows show respective position of the construct at 
the 5’-flanking region of the gene.  The relative promoter activities of various constructs, 
after normalized by the activity of the pGL3-Basic vector (Basic), were shown on the right 
This figure represents the mean of three individual transfection experiments. 
 
Figure 6:  Promoter assays in different human cell lines.  The relative promoter activities 
of all cell lines were normalized by the pGL3-Basic activity.  The figure represents the mean 
of two individual transfection experiments. 
 
Figure 7:  Gel-shift assays.  8 ìg of PANC-1 nuclear extracts were used for each individual 
reaction.  (A) Gel shift was only observed in the L6 DNA probe, corresponding to the 
sequence –96 to –76 of the human C1qBP gene.  (B) Competition assay was performed 
using 8 mg of the PANC-1 nuclear extracts in the presence of an increasing concentration of 
unlabeled DNA probe (0, 10 and 100 fold).  The formation of DNA-protein complexes was 
gradually inhibited only by the specific oligo but not by an unrelated oligo.  In the negative 
control experiments (-ve) using an unrelated oligo, only the formation of DNA-protein 
complex 1 was inhibited but the formation of the other 3 complexes were not disturbed.  
This showed that DNA-protein complex 1 was an artifact.   
 
Figure 8:  Supershift assay was performed using the L6 oligo as a probe.  When 4 mg of 
anti-Sp1 antibodies were added to the mixture, the band of DNA-protein complex 4 shifted 
upwards from its original position (as shown when no antibody was added) while the other 
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three bands were unaffected.  DNA-protein complex 4 should be a complex of oligo L6 and 
the transcription factor Sp1.  BSA was used as the negative control in this assay, which was 
unable to display the DNA-protein complex 4. 
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Table 1.  Primers designed for construction of recombinant plasmids and gel shift assays.
(A) Primers designed for construction of recombinant plasmids.
Primers Primer sequences (4 bases and RE sites added at 5') Position in 5' flanking region
Pro0Sac 5' attaGAGCTC CTGCCCTTGAGGATG 3' -1314 to '-1300
Pro200Sac 5' attaGAGCTC AACAATCAACACAGAAGACTT 3' -1121 to -1101
Pro400Sac 5' attaGAGCTC CGACCAACCCGCTTCA 3' -916 to -901
Pro600Sac 5' attaGAGCTC CAGGAACCTCTACG 3' -713 to -702
Pro800Sac 5' attaGAGCTC GTTGTTTCCTGAGGCCT 3' -506 to -489
Pro954Sac 5' attaGAGCTC GTGGAAGGGTCTGGT 3' -364 to -350
G1A2Bgl 5' attaGATCTC GCGGAAACGACTGCGAA 3' -18 to -1 (inverted)
Pro0Bgl 5' attaGATCTC CTGCCCTTGAGGATG 3' -1314 to -1300
G1A2Sac 5' attaGAGCTC GCGGAAACGACTGCGAA 3' -18 to -1 (inverted)
(B) Primers for gel shift assays.  All primers were designed from their GC contect with respect to their
location in the 5' flanking region of the human gC1qBP gene.  "S" indicates sense primers and "A" is the 
antisense version of its sense primer.  L8S and L8A, which do not contain GC-rich sequences, were 
designed as negative controls.
Primers Primer sequences (4 bases and RE sites added at 5') Position in 5' flanking region
L1S 5'  AGAGCTGGCG GGAGACAA 5'  -348 to -331
L1A 3'  TTGTCTCCCG CCAGCTCT 3' -331 to -348
L2S 5'  AGGCTTCCCG GGCTGCAC 5' -188 to -171
L2A 3'  GTGCAGCCCG GGAAGCCT 3' -171 to -188
L3S 5'  AGCAGAGGGC GCGATTCCG 5' -160 to -142
L3A 3'  CGGAATCGCG CCCTCTGCT 3' -142 to -160
L4S 5'  GCGATTCCGC CCGCTGGC 5' 150 to -133
L4A 3'  GCCAGCGGGC GGAATCGC 3' -133 to -150
L5S 5'  GAGCGCCGGC GCGGGAAGC 5' -120 to -102
L5A 3'  GCTTCCCGCG CCGGCGCTC 3' -102 to -120
L6S 5'  CGGGCAGGGG CGGGGCTTCC G 5' -96 to -76
L6A 3'  CGGAAGCCCC GCCCCTGCCC C 3' -76 to -96
L7S 5'  TCAGGTCGCG GGGCGCCTAG 5' -67 to -48
L7A 3'  CTAGGCGCCC CGCGACCTGA 3' -48 to -67
L8S 5'  GGCCACTAGA GGGAATTAAA 5' -264 to -245
L8A 3'  TTTAATTCCC TCTAGTGGCC 3' -245 to -264
 
Table 2. Expression plasmids for luciferase promoter assay. 
Constructs Primers employed RE sites  
at 5’ end  
RE sites  
at 3’ end 
Fragment size deletion  
from  
RES 1 Pro0Bgl + G1A2Sac Bgl II Sac I 1.3 kb Nil (reverse) 
RES 2 Pro0Sac + G1A2Bgl Sac I Bgl II 1.3 kb Nil 
RES 3 Pro200Sac + G1A2Bgl Sac I Bgl II 1.1 kb 5’ 
RES 4 Pro400Sac + G1A2Bgl Sac I Bgl II 0.9 kb 5’ 
RES 5 Pro600Sac + G1A2Bgl Sac I Bgl II 0.7 kb 5’ 
RES 6 Pro800Sac + G1A2Bgl Sac I Bgl II 0.5 kb 5’ 
RES 7 Pro954Sac + G1A2Bgl Sac I Bgl II 0.4 kb 5’ 
RES 2H Pro0Sac + G1A2Bgl Sac I Hind III  0.67 kb 3’ 
RES 2P Pro0Sac + G1A2Bgl Sac I PsPA I 1.1 kb 3’ 
 
Table 3.  Exon-intron boundaries of the human C1qBP gene. 
 
exon 
no. 
location  
on cDNA 
exon 
size 
exon 5' seq exon 3' seq intron 
no. 
intron 5' seq intron 3' seq intron 
size 
amino acid 
interrupted 
1 1-232 232bp  CACACCGACG 1 GTGAGGTTTA TCTTTTCTAG 568bp glycine-78 
2 233-383 151bp GAGACAAAGC CCGGGGAAAA 2 GTAAGTACTG GCCGTTTTAG 3156bp lysine-128 
3 384-477 94bp AATCACGGTC AGAACAGGAG 3 GTAAGCTAAT GTTTCCCCAG 1104bp NIL 
4 478-576 99bp CCTGAACTGA AGAGGATGAG 4 GTATGCAGGA TTCTTCTCAG 253bp NIL 
5 577-699 123bp GTTGGACAAG CTTGGACTGG 5 GTGAGTGCTT TTCTTTGCAG 128bp NIL 
6 700-845 516bp GCCTTATATG       
The exon-intron boundaries follow the GT/AG rule (as indicated by bold letters). 
B
am
H
I
0.5kb
H
in
dI
II
    gIIIgIIgI
gVI   gIV
B
am
H
I
P
st
I
S
ac
I
S
ac
IS
m
aIX
ba
I
X
ba
I
X
ba
I
gV
H
in
dI
II
S
m
aI
Figure 1
-1311 tcctgccctt gaggatgtca cagtctggtt gggttta ………………5' flanking region
………………………… ……………………………………………………… catctgcacg tgttcgcagt cgtttccgcg
1 ATGCTGCCTC TGCTGCGCTG CGTGCCCCGT GTGCTGGGCT CCTCCGTCGC CGGCCTCCGC
61 GCTGCCGCGC CCGCCTCGCC TTTCCGGCAG CTCCTGCAGC CGGCACCCCG GCTGTGCACC
121 CGGCCCTTCG GGCTGCTCAG CGTGCGCGCA GGTTCCGAGC GGCGGCCGGG CCTCCTGCGG
181 CCTCGCGGAC CCTGCGCCTG TGGCTGTGGC TGCGGCTCGC TGCACACCGA CGgtgaggtt
241 tagcgggccg ………………………… …………………………………… intron 1  (568bp) …………………………
………………………… ………………………… ………………………… ………………………… tatctggatt tcttttctag
801 GAGACAAAGC TTTTGTTGAT TTCCTGAGTG ATGAAATTAA GGAGGAAAGA AAAATTCAGA
861 AGCATAAAAC CCTCCCTAAG ATGTCTGGAG GTTGGGAGCT GGAACTGAAT GGGACAGAAG
921 CGAAATTAGT GCGGAAAGTT GCCGGGGAAA Agtaagtact ggtctgggga …………………………
………………intron 2 (3156bp)……………………… ………………………… cttgtctgtt ttcccttgcc
4101 gttttagAAT CACGGTCACT TTCAACATTA ACAACAGCAT CCCACCAACA TTTGATGGTG
4161 AGGAGGAACC CTCGCAAGGG CAGAAGGTTG AAGAACAGGA Ggtaagctaa tactataatc
…………………………intron 3 (1104bp) ………… ………………………… ttcttgtttc cccagCCTGA
5311 ACTGACATCA ACTCCCAATT TCGTGGTTGA AGTTATAAAG AATGATGATG GCAAGAAGGC
5371 CCTTGTGTTG GACTGTCATT ATCCAGAGGA TGAGgtatgc aggatggagt …………………………
………………………… intron 4 (253bp)…………… ………………ccca atattgtttc ttctcagGTT
5661 GGACAAGAAG ACGAGGCTGA GAGTGACATC TTCTCTATCA GGGAAGTTAG CTTTCAGTCC
5721 ACTGGCGAGT CTGAATGGAA GGATACTAAT TATACACTCA ACACAGATTC CTTGGACTGG
5781 gtgagtgctt gataaggtgg ………………………… ………………………… intron 5 (128bp)……………
………………………… ………………………… ………………………… tttaactagt aaatattgtt ctttgcagGC
5911 CTTATATGAC CACCTAATGG ATTTCCTTGC CGACCGAGGG GTGGACAACA CTTTTGCAGA
5971 TGAGCTGGTG GAGCTCAGCA CAGCCCTGGA GCACCAGGAG TACATTACTT TTCTTGAAGA
6031 CCTCAAGAGT TTTGTCAAGA GCCAGTAGAG CAGACAGATG CTGAAAGCCA TAGTTTCATG
6091 GCAGGCTTTG GCCAGTGAAC AAATCCTACT CTGAAGCTAG ACATGTGCTT TGAAATGATT
6151 ATCATCCTAA TATCATGGGG GAAAAAATAC CAAATTTAAA TTATATGTTT TGTGTTCTCA
6211 TTTATTATCA TTTTTTTCTG TACAAATCTA TTATTTCTAG ATTTTTGTAT AACATGATAG
6271 ACATAAAATT GGTTTATCTC CTCCAAGGCA GTTTGTCTTT TTCTATTCCT CCCCCTTCAA
6331 CCTGCGTCAC AAAAGACCAA GAACAGATGT CGGAAAAGTT TTTTTTTCTT CAGTATTGTT
6391 TAAAAGTTTC AATACAAAAT AAGTTATAAA TAAAaggctt gtatgtacaa ggctcctcag
6451 agggaatgag ttgtcttcaa ccccatagaa tgatgtgagt c
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-1374                                                            GGATC
-1314 CTGCCCTTGA GGATGTCACA GTCTGGTTGG GTTTAACCTG GTTAAAGCAG CAACGCTAGG
SP1
-1254 AGGTTCCTGT TGAAAAGAGA ATGAAGCATA TGGGCTGGGT GCGCACAAGC ATGAGTTCCG
-1194 AGCCGGTGGA AAAAAAGGTT CTAGAAGGCC TCTTTCAGGA AAACCCTCAG ACTTTCCTTT
NFAT STAT/NFAT
-1134 GCTCTCACAA CACAACAATC AACACAGAAG ACTTATGTGG CCAAAGGTTT GGGTTTTTCC
-1074 CCTCCACACT AAGCAGCAGA CACCAGCTGG GTGTCCTCCA ATTCAATCCC AACAGTATCT
AP4 CAAT box
-1014 ACCTGGAGAT AGTGTCAGAT CCCATAGGTT GAGGGCTCAG TCCCCAAGAC CGCCCCCACC
GATA                AP2      SP1
-954  TTCAGACAGC AATGGCAAGT CTGGGCCTCT GAAACTTCCG ACCAACCCGC TTCAAGTTGG
HSF
-894  GGTTCCCACG ACCCCCCTCT TTGGATTATG TTAACTCACT GGAGCAGTTC ACAGAACTCA
AP3
-834  GGGAAACACA TTCACCGGTT TCATATAAAG GATATGACCA AGGATACAGA TGAGATGAGC
TATA box  GATA
-774  AGGGTGGGGA ATGGGGAAGA AGCTCCGAGG TTCCTTGCCT ACCCTGGGCC ACCACCCTCC
AP2     AP2
-714  AGGAACCTCT ACGTATTCAG CTGTCAGAGG CTCTGCAAAC CCTCTCCTCT TGGGTTTTTA
-654  TGGAAGCTTC TGGACATCAG CATCCCTTCC CCCAGGGTAT ATGGTGGGAC CTTCTCTGGG
HSF                               TATA box
-594  AAGGGACTTA AGACCCATAA TCAGAAATGT GGAAGGAGAT TAGAGTCCTG CTTTGGGGCA
AP1              GATA      SP1
-534  GGTAAAAGGA GGGCAGGAGA AGGGGAGAGT CTGTTTCCTG AGGCCTAACA CACCCAACAT
C/EBP  SP1 NFAT
-474  TATCACAGAA CATTGTAACA AGGGCTATAG GAGTTACGAC CCAGGAACTG TGGATGAAAA
CAAT box        TATA box
-414  CCAATACATA TATATATCAT AACACCACAG CCTCCTAGAG GAAAGTGACC GTGGAAGGGT
CAAT box TATA box AML             NFAT 
-354  CTGGTGAGAG CTGGCGGGAG ACAAGAGTGC ATTCCACGCA GCCCAAAAGC CTTGCGTGCT
SP1
-294  TTGAGAACAG CAGGTGGAAA GTGGGTAAGC GGCCACTAGA GGGAATTAAA CAGCTTCGGA
-234  CAGCGGACTC GGCAGCGCAG CAAGAAAGCT CCGGAATCCG GATTCGAGGC TTCCCGGGCT
HSF                            SP1
-174  GCACCGGAGT CTCCAGCAGA GGGCGCGATT CCGCCCGCTG GCCTTAGGTC GTCAGAGCGC
SP1      SP1 AP2
-114  CGGCGCGGGA AGCGCTTCCG GGCAGGGGCG GGGCTTCCGG CGGCGCCTCA GGTCGCGGGG
SP1         c-Ets-1       SP1   c-Ets-1                    SP1
-54   CGCCTAGGCC TGGGTTGTCC TTTGCATCTG CACGTGTTCG CAGTCGTTTC CGCGATGCTG
Oct-1
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